NADAC acquisition cost data for PODOFILOX 0.5% TOPICAL SOLN. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00574061105 | $12.95 | 2022-12-21 | Rx |
| 00591320413 | $12.95 | 2022-12-21 | Rx |
| 00574061105 | $12.95 | 2022-12-21 | Rx |
| 00591320413 | $12.95 | 2022-12-21 | Rx |
Generic: Podofilox | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $354.3K | 5,890 | 3,739 | $15.77 |
| 2020 | $329.7K | 5,325 | 3,357 | $15.93 |
| 2021 | $332.8K | 5,411 | 3,577 | $16.18 |
| 2022 | $317.9K | 5,232 | 3,545 | $16.10 |
| 2023 | $348.5K | 5,806 | 3,737 | $16.07 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $48.9K | 984 | 647 |
| Florida | $35.1K | 523 | 331 |
| Texas | $25.8K | 427 | 296 |
| New York | $22.3K | 387 | 228 |
| Michigan | $16.2K | 260 | 157 |
| Ohio | $13.6K | 222 | 133 |
| New Jersey | $12.0K | 203 | 117 |
| Pennsylvania | $11.8K | 189 | 118 |
| Puerto Rico | $11.6K | 161 | 118 |
| Illinois | $10.2K | 162 | 98 |
| North Carolina | $8.6K | 131 | 95 |
| Tennessee | $8.6K | 135 | 85 |
| Georgia | $7.8K | 130 | 84 |
| Washington | $7.2K | 123 | 87 |
| Minnesota | $6.9K | 99 | 53 |
| Massachusetts | $6.7K | 111 | 76 |
| Oklahoma | $6.0K | 99 | 66 |
| Indiana | $6.0K | 80 | 63 |
| Arizona | $5.8K | 94 | 65 |
| Louisiana | $5.8K | 88 | 54 |
| Virginia | $5.3K | 78 | 55 |
| Kentucky | $5.3K | 81 | 54 |
| Alabama | $4.9K | 78 | 57 |
| Connecticut | $4.9K | 68 | 32 |
| South Carolina | $4.7K | 74 | 44 |
| Colorado | $4.3K | 81 | 48 |
| Mississippi | $4.2K | 65 | 41 |
| Oregon | $4.1K | 78 | 48 |
| Wisconsin | $3.9K | 67 | 43 |
| Missouri | $3.7K | 57 | 47 |
| Kansas | $3.2K | 50 | 35 |
| Arkansas | $2.9K | 45 | 33 |
| New Mexico | $2.6K | 44 | 23 |
| Maine | $2.3K | 42 | 28 |
| Nevada | $1.9K | 38 | 21 |
| Maryland | $1.7K | 35 | 30 |
| West Virginia | $1.6K | 25 | 18 |
| Utah | $1.5K | 24 | 16 |
| New Hampshire | $1.3K | 20 | 18 |
| Iowa | $1.3K | 20 | 16 |
| Vermont | $1.2K | 16 | N/A |
| Rhode Island | $1.0K | 15 | 12 |
| Hawaii | $1.0K | 19 | 16 |
| Idaho | $797.31 | 15 | 11 |
| Nebraska | $780.96 | 11 | 11 |
| Delaware | $651.04 | 12 | 11 |
| North Dakota | $572.84 | 13 | N/A |
| Montana | $510.97 | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.